Mirae Asset Healthcare Growth Direct Plan
SIP amount
Min. ₹99
Lumpsum amount
Min. ₹5,000

Mirae Asset Healthcare Growth Direct Plan

NAV
₹43.4000
-2.03%
(13 Mar)
AUM
2,844 Cr
TER
0.47%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+25.4%
+24.1%
+23.9%
+19.2%
+13.2%
3Y
+32.8%
+31.0%
+29.8%
+28.8%
+26.9%
5Y
+27.1%
+25.4%
+26.4%
NA
+17.4%
ALL
+12.2%
+16.5%
+24.2%
+26.1%
+20.8%
VOL
20.0%
19.6%
21.8%
17.2%
15.8%
TER
0.8%
0.9%
0.6%
0.9%
0.5%
AUM
₹6,545 Cr
₹1,511 Cr
₹6,086 Cr
₹2,022 Cr
₹2,844 Cr
INFO
0.61
0.84
1.11
1.51
1.32
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Mirae Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 28th Feb
Top holdings
Sun Pharmaceuticals Industries Ltd
11.8%
Divi's Laboratories Ltd
8.2%
Glenmark Pharmaceuticals Ltd
6.9%
J.B. Chemicals & Pharmaceuticals Ltd
6.6%
Apollo Hospitals Enterprise Ltd
6.4%
Lupin Ltd
5.1%
Cipla Ltd
4.8%
Fortis Healthcare Ltd
4.3%
Dr Reddy's Laboratories Ltd
4.3%
Aurobindo Pharma Ltd
3.9%
Top industry exposure
Healthcare
98.7%
Basic Materials
1.0%
Other information
Minimum SIP
₹99
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
31%
Lock-in period
-
Exit load
• 1% for redemption within 365 days
Fund objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sectors in India. The Scheme does not guarantee or assure any returns.
Fund manager(s)
Vrijesh Kasera
Tanmay Mehta

FAQs